Distribution Deals in Medical Devices 2016-2026
Distribution Deals in Medical Devices | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2026
Benchmark Global Distribution Partnerships Across the Medical Device Industry
This latest Distribution Deals in Medical Devices report provides a comprehensive analysis of distribution partnerships across the global medical device sector. Designed for business development, licensing, and commercial strategy professionals, the report delivers detailed insight into how companies structure distribution agreements, negotiate financial terms, and expand market access through strategic partnerships.
Fully revised and updated, the report examines distribution deals announced between 2016 and 2026, providing a clear view of how device manufacturers collaborate with distribution partners to reach new markets and accelerate commercialization.
The report contains a comprehensive listing of distribution deals recorded in the Current Agreements deals and alliances database, including financial terms where available and links to online deal records. Where agreements have been publicly filed, the report also provides access to the underlying contract documents submitted to the SEC, enabling deeper insight into how distribution partnerships are structured in practice.
Whether you are benchmarking deal structures, identifying distribution partners, or performing due diligence on commercialization strategies, this report provides the real-world deal data and contract intelligence needed to structure stronger distribution agreements.
Key Benefits
✔ Save Significant Research Time
Access a consolidated database of distribution deals instead of searching multiple press releases, databases, and regulatory filings.
✔ Benchmark Distribution Deal Structures
Understand how medical device companies structure distribution partnerships, including territorial rights, commercialization responsibilities, and operational roles.
✔ Analyze Financial Deal Terms
Review disclosed payment structures and commercial terms to benchmark the financial structure of comparable distribution partnerships.
✔ Access Real Contract Documents
Where available, explore SEC-filed distribution agreements, providing insight into the detailed contractual provisions behind real-world partnerships.
✔ Identify the Most Active Distribution Dealmakers
Discover which companies are leading distribution partnerships across the medical device sector and analyze their commercialization strategies.
✔ Track Industry Trends
Analyze distribution deal activity since 2016 across companies, therapeutic areas, and technology segments to understand how device commercialization strategies are evolving.
What’s Included in the Report
-
Analysis of distribution dealmaking trends since 2016
-
Overview of distribution partnership structures and financial models
-
Review of leading distribution deals by disclosed value
-
Profiles of the most active distribution dealmakers
-
Detailed analysis of deals organized by company, therapeutic area, and technology type
-
A comprehensive directory of distribution deals recorded in the Current Agreements database
-
Links to online deal records and contract documents where available
Due Diligence Insights from Real Agreements
By reviewing actual distribution contracts, the report allows users to evaluate key partnership provisions such as:
-
Territorial distribution rights
-
Commercial responsibilities between partners
-
Payment structures and commercial terms
-
Exclusivity provisions
-
Supply and commercialization obligations
-
Contract duration and termination provisions
Why This Report Matters
Distribution partnerships are critical to the global commercialization of medical devices, enabling companies to expand market reach, accelerate product launches, and access regional expertise.
By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to structure stronger distribution partnerships and negotiate more effectively.
Key Benefits
✔ Save Significant Research Time
Access a consolidated database of distribution deals instead of searching multiple press releases, databases, and regulatory filings.
✔ Benchmark Distribution Deal Structures
Understand how medical device companies structure distribution partnerships, including territorial rights, commercialization responsibilities, and operational roles.
✔ Analyze Financial Deal Terms
Review disclosed payment structures and commercial terms to benchmark the financial structure of comparable distribution partnerships.
✔ Access Real Contract Documents
Where available, explore SEC-filed distribution agreements, providing insight into the detailed contractual provisions behind real-world partnerships.
✔ Identify the Most Active Distribution Dealmakers
Discover which companies are leading distribution partnerships across the medical device sector and analyze their commercialization strategies.
✔ Track Industry Trends
Analyze distribution deal activity since 2016 across companies, therapeutic areas, and technology segments to understand how device commercialization strategies are evolving.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in distribution dealmaking
2.1. Introduction
2.2. Definition of distribution deal
2.3. Trends in distribution deals since 2016
2.3.1. Distribution dealmaking by year
2.3.2. Distribution dealmaking by phase of development
2.3.3. Distribution dealmaking by therapy area
2.3.4. Distribution dealmaking by technology type
2.3.5. Distribution dealmaking by most active company
2.3.6 Attributes of pure distribution deals
2.3.7 Attributes of distribution in multi-component deals
2.4. Aligning partners to make the distribution agreement work
Chapter 3 – Overview of distribution deal structure
3.1. Introduction
3.2. Distribution agreement structure
3.3 Distribution rights as part of a wider alliance agreement
Chapter 4 – Leading distribution deals
4.1. Introduction
4.2. Top distribution deals by value
Chapter 5 – Top 25 most active distribution dealmakers
5.1. Introduction
5.2. Top 25 most active distribution dealmakers
Deal directory
Deal directory – distribution dealmaking by companies A-Z
Deal directory – distribution dealmaking by therapy area
Deal directory – distribution dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of distribution
Figure 2: Trends in distribution deal announcements
Figure 3: Distribution deals signed at each phase of development
Figure 4: Distribution deals by therapy area
Figure 5: Distribution deals by technology type
Figure 6: Top 25 most active distribution dealmakers
Figure 7: Issues in implementing distribution agreements
Figure 8: Distribution agreements – what should a contract include?
Figure 9: Components of the distribution deal structure
Figure 10: Top distribution deals by value
Figure 11: Most active distribution dealmakers
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in County Durham, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
-
Company press releases and announcements
-
SEC filings and equivalent regulatory disclosures
-
Company and investor presentations
-
Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
-
Licensing and co-development
-
Research and collaborative R&D
-
Manufacturing, supply, and distribution
-
Commercialisation and co-promotion
-
Equity investments, joint ventures, and asset transactions
-
Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
-
Financial terms — including upfront payments, milestones, and royalties
-
Rights allocation — development, manufacturing, and commercialization responsibilities
-
Deal structure — exclusivity, territorial scope, and agreement type
-
Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
-
Therapy area and technology type
-
Stage of development
-
Asset type and deal components
-
Geographic scope and exclusivity
-
Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
-
How financial mechanisms are defined and triggered
-
How responsibilities are operationalised between parties
-
How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making, including:
-
Benchmarking comparable transactions
-
Supporting valuation and deal structuring
-
Preparing for negotiations
-
Evaluating potential partners
-
Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies and emerging biotechs as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.


